margetuximab

Home
Ligands
margetuximab

GtoPdb Ligand ID: 8686

Synonyms: Margenza® | margetuximab-cmkb | MGAH-22

margetuximab is an approved drug (FDA (2020))

Comment: Margetuximab is a chimeric monoclonal antibody targeting epidermal growth factor receptor 2 (ERBB2).
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. Peptide sequence search of patented sequences reveals a 100% match between the heavy chain variable domain of margetuximab and SEQ ID NO: 13 from patent US8802093 B2, and antibody clone ch4D5-FcMT3 [2]. Although the patent describes performing Biacore assays to determine antibody-target (ERBB2) affinity, a K_D value is not provided.

References
1. Catenacci DV, Rosales M, Chung HC, H Yoon H, Shen L, Moehler M, Kang YK. (2021) MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma. Future Oncol, 17 (10): 1155-1164. [PMID:33263418]
2. Johnson LS, Huang L, Tuaillon N, Bonvini E. (2014) HER2/neu-specific antibodies and methods of using same. Patent number: US8802093 B2. Assignee: Macrogenics, Inc.. Priority date: 02/04/2008. Publication date: 12/08/2014.

References

1. Catenacci DV, Rosales M, Chung HC, H Yoon H, Shen L, Moehler M, Kang YK. (2021)
MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma.
Future Oncol, 17 (10): 1155-1164. [PMID:33263418]

2. Johnson LS, Huang L, Tuaillon N, Bonvini E. (2014)
HER2/neu-specific antibodies and methods of using same.
Patent number: US8802093 B2. Assignee: Macrogenics, Inc.. Priority date: 02/04/2008. Publication date: 12/08/2014.